Vaccinex, Inc.
Cash Flow Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-18.6M | $-20.3M | $-19.8M | $-22.4M | $-28.9M | $-31.9M | $-29.5M | $-18.7M |
| Depreciation & Amortization | — | — | — | — | — | $249.0K | $223.0K | $206.0K |
| Depreciation | $94.0K | $119.0K | $207.0K | $169.0K | $307.0K | $249.0K | $223.0K | $206.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $341.0K | $474.0K | $545.0K | $541.0K | $732.0K | $447.0K | $177.0K | $319.0K |
| Net Cash from Operating Activities | $-16.2M | $-21.4M | $-19.1M | $-25.3M | $-28.6M | $-30.7M | $-25.3M | $-21.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $22.0K | $67.0K | $99.0K | $32.0K | $290.0K | $78.0K | $235.0K | $68.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-22.0K | $-67.0K | $-99.0K | $-32.0K | $-290.0K | $14.1M | $-14.2M | $-68.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $15.8M | $16.6M | $17.0M | $23.3M | $36.8M | $13.8M | $41.0M | $24.0M |
| Net Change in Cash | $-428.0K | $-4.9M | $-2.2M | $-2.0M | $7.8M | $-2.8M | $1.4M | $2.5M |
| Free Cash Flow | $-16.2M | $-21.4M | $-19.2M | $-25.3M | $-28.9M | $-30.8M | $-25.5M | $-21.5M |